NUT family member 2A (NUTM2A)

NUT family member 2A (NUTM2A) is a human protein encoded by the NUTM2A gene, located on chromosome 19. It produces a protein of 878 amino acids (~93.9 kDa)[1][3]. NUTM2A itself does not belong to major receptor or enzyme classes, nor is it known to have a direct signaling or metabolic function[3]. Its primary relevance is as a fusion partner in a subset of cancers, most notably endometrial stromal sarcoma, where the YWHAE-NUTM2A gene fusion defines a molecular subtype with high-grade features and distinct clinical implications[8]. Similar chromosomal rearrangements involving NUTM2A have been described in other sarcomas and rare fusion-driven tumors[4]. NUTM2A is not directly targeted by approved therapeutic agents, but its fusion status can serve as a diagnostic or prognostic biomarker[8]. While some research has focused on gene expression and the impact of NUTM2A fusions, the molecular and cellular functions of native NUTM2A protein in normal physiology remain poorly characterized[3]. Essential context and details: - NUTM2A is not known to be a traditional "therapeutic target" such as a receptor, enzyme, or transporter[3][8]. - Its primary clinical significance is as a fusion gene in cancer: the YWHAE-NUTM2A rearrangement is highly specific for a subset of endometrial stromal sarcomas and other sarcomas[8][4]. - No specific drugs are known to target NUTM2A directly, though its fusion may serve as a molecular marker for diagnosis or future targeted therapy[8][4]. - Synonyms include FAM22A and KIAA2020. Sometimes confusion may arise with the antisense RNA NUTM2A-AS1, which is a distinct long noncoding RNA with roles in cancer biology, but does not encode the protein described here[2][5]. - There is no evidence for a major physiological function or major role in canonical cell biology; most significance derives from its implication in oncogenic fusions[3][8].

Other names

FAM22AKIAA2020Protein FAM22AFamily with sequence similarity 22, member ANUTM2A

null (no direct drug mechanism established; fusions may provide indirect actionable mechanisms in oncology)